Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants

JAMA - Journal of the American Medical Association

Volumn 313, Issue 11, 2015, Pages 1133-1142

  Nan, Hongmei ^a,b   Hutter, Carolyn M ^c   Lin, Yi ^d   Jacobs, Eric J ^e   Ulrich, Cornelia M ^d,f   White, Emily ^d,g   Baron, John A ^h   Berndt, Sonja I ⁱ   Brenner, Hermann ^j   Butterbach, Katja ^j   Caan, Bette J ^k   Campbell, Peter T ^e   Carlson, Christopher S ^d   Casey, Graham ^l   Chang Claude, Jenny ^j   Chanock, Stephen J ⁱ   Cotterchio, Michelle ^m   Duggan, David ⁿ   Figueiredo, Jane C ^l   Fuchs, Charles S ^o   Giovannucci, Edward L ^p   Gong, Jian ^d   Haile, Robert W ^l   Harrison, Tabitha A ^d   Hayes, Richard B ^q   Hoffmeister, Michael ^j   Hopper, John L ^r   Hudson, Thomas J ^s,t   Jenkins, Mark A ^r   Jiao, Shuo ^d   Lindor, Noralane M ^u   Lemire, Mathieu ^t   Le Marchand, Loic ^v   Newcomb, Polly A ^d   Ogino, Shuji ^o,p,w   Pflugeisen, Bethann M ^d   Potter, John D ^d,x   Qu, Conghui ^d   Rosse, Stephanie A ^d   Rudolph, Anja ^j   Schoen, Robert E ^y   Schumacher, Fredrick R ^l   Seminara, Daniela ^c   Slattery, Martha L ^z   Thibodeau, Stephen N ^aa   Thomas, Fridtjof ^ab   Thornquist, Mark ^d   Warnick, Greg S ^d   Zanke, Brent W ^ac   Gauderman, W James ^l   Peters, Ulrike ^d,g   Hsu, Li ^d,g   Chan, Andrew T ^p,ad   more..

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e AMERICAN CANCER SOCIETY   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^k DIVISION OF RESEARCH   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m CANCER CARE ONTARIO   (Canada)

ⁿ TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p BRIGHAM AND WOMEN S HOSPITAL   (United States)

^q NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY OF MELBOURNE   (Australia)

^s UNIVERSITY OF TORONTO   (Canada)

^t ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^u MAYO CLINIC   (United States)

^v UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^w HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^x MASSEY UNIVERSITY   (New Zealand)

^y UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^z UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^aa MAYO CLINIC   (United States)

^ab UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^ac OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^ad MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INTERLEUKIN 16; NONSTEROID ANTIINFLAMMATORY AGENT; GENETIC MARKER;

ARTICLE; AUSTRALIA; CANADA; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CHROMOSOME 12; CHROMOSOME 15Q; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EUROPEAN; GENE INTERACTION; GENETIC CORRELATION; GENETIC VARIABILITY; GENOTYPE; GERMANY; HUMAN; IL16 GENE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; CHROMOSOME 15; COLORECTAL NEOPLASMS; FEMALE; GENETIC MARKER; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MALE; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 15; COLORECTAL NEOPLASMS; FEMALE; GENE-ENVIRONMENT INTERACTION; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84929390853     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1815     Document Type: Article

References (40)

1. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914-923.
2. Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573): 1603-1613.
3. Friis S, Poulsen AH, Sørensen HT, et al. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control. 2009;20(5):731-740.
4. García Rodríguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11(4): 376-381.
5. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-1750.
6. Hutter CM, Chang-Claude J, Slattery ML, et al. Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res. 2012;72(8):2036-2044.
7. Hutter CM, Slattery ML, Duggan DJ, et al. Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis. BMC Cancer. 2010;10:670.
8. Makar KW, Poole EM, Resler AJ, et al. COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. Cancer Causes Control. 2013;24(12):2059-2075.
9. Nan H, Morikawa T, Suuriniemi M, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105 (24):1852-1861.
10. Seufert BL, Poole EM, Whitton J, et al. IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis. 2013;34(1):79-85.
11. Jiao S, Hsu L, Hutter CM, Peters U. The use of imputed values in the meta-analysis of genome-wide association studies. Genet Epidemiol. 2011;35(7):597-605.
12. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10: 101-129.
13. Pfeiffer RM, Gail MH, Pee D. On combining data from genome-wide association studies to discover disease-associated SNPs. Stat Sci. 2009;24(4):547-560.
14. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet. 2013;14(6):379-389.
15. Begum F, Ghosh D, Tseng GC, Feingold E. Comprehensive literature review and statistical considerations for GWAS meta-analysis. Nucleic Acids Res. 2012;40(9):3777-3784.
16. Prage EB, Pawelzik SC, Busenlehner LS, et al. Location of inhibitor binding sites in the human inducible prostaglandin E synthase, MPGES1. Biochemistry. 2011;50(35):7684-7693.
17. Morgenstern R, Zhang J, Johansson K. Microsomal glutathione transferase 1: mechanism and functional roles. Drug Metab Rev. 2011;43(2): 300-306.
18. Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW. mPGES-1 as a target for cancer suppression: a comprehensive invited review "Phospholipase A2 and lipid mediators." Biochimie. 2010;92(6):660-664.
19. Castellone MD, Teramoto H, Gutkind JS. Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Res. 2006;66(23):11085-11088.
20. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005; 310(5753):1504-1510.
21. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem. 2003;278(21):19396-19405.
22. Murakami M, Naraba H, Tanioka T, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem. 2000;275(42): 32783-32792.
23. Sherratt PJ, McLellan LI, Hayes JD. Positive and negative regulation of prostaglandin E2 biosynthesis in human colorectal carcinoma cells by cancer chemopreventive agents. Biochem Pharmacol. 2003;66(1):51-61.
24. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001;20 (5):645-653.
25. Gala MK, Chan AT. Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment [published online December 11, 2014]. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-0877.
26. Kwon YJ, Lee SJ, Koh JS, et al. Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. J Thorac Oncol. 2012;7(1):20-33.
27. Aoyama M, Ozaki T, Inuzuka H, et al. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res. 2005;65(11):4587-4597.
28. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193-204.
29. Kaur J, Sanyal SN. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol. 2010; 31(6):623-631.
30. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596-1606.
31. Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31 (34):4297-4305.
32. Azimzadeh P, Romani S, Mohebbi SR, et al. Interleukin-16 (IL-16) gene polymorphisms in Iranian patients with colorectal cancer. J Gastrointestin Liver Dis. 2011;20(4):371-376.
33. Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000;67(6):757-766.
34. Gerhard R, Queisser S, Tatge H, et al. Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B. Naunyn Schmiedebergs Arch Pharmacol. 2011;383 (3):285-295.
35. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011; 70(suppl 1):i104-i108.
36. Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets. 2011;11(4):451-464.
37. Symmons O, Uslu VV, Tsujimura T, et al. Functional and topological characteristics of mammalian regulatory domains. Genome Res. 2014;24(3):390-400.
38. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5(2):164-178.
39. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38(2):209-213.
40. Pearce CL, Rossing MA, Lee AW, et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(5):880-890.